During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What are the latest findings from the phase I/II study of nuvisertib in combination with momelotinib in patients with relapsed/refractory myelofibrosis (R/R MF)?

In this interview, Harrison discusses key findings from Arm 3 of the trial (NCT04176198), which enrolled patients who had been previously treated with a Janus kinase inhibitor (JAKi) other than momelotinib. The study aimed to identify the recommended phase II dose (RP2D) of nuvisertib when administered in combination with momelotinib, and to assess the safety, clinical activity (spleen volume reduction [SVR] and total symptom score [TSS] improvement), and pharmacokinetics and pharmacodynamic markers (including cytokines and bone marrow fibrosis).

This educational resource is independently supported by Sumitomo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with Jean-Jacques Kiladjian, Université Paris Cité, Paris, FR. We asked, What are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study?

In this interview, Kiladjian first provided an overview of the phase III ROP-ET (NCT06514807) study design and key patient eligibility criteria. He then discussed the primary endpoint results, highlighting that the ROP-ET study met the primary endpoint – a composite durable hematologic and clinical response after 12 months. Finally, Kiladjian explored the safety profile of ropeginterferon alfa-2b observed in the study.

This educational resource is independently supported by AOP Health. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The MPN Hub was pleased to speak with Jennifer Vaughn, The Ohio State University Comprehensive Cancer Center, Columbus, US. We asked, How might extended-release formulations of ruxolitinib benefit patients with MF?

In this interview, Vaughn discusses the potential benefits of an extended-release ruxolitinib formulation for patients with myelofibrosis, noting that ruxolitinib’s short half-life necessitates twice-daily dosing, which may reduce adherence. Vaughn highlights that an extended-release formulation, enabling once-daily dosing, may improve adherence, maintain disease control, and lessen cytopenias.

This educational resource is independently supported by Incyte. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.